Khosla Ven­tures leads $38M seed round for organoid start­up Vivo­dyne

Khosla Ven­tures is lead­ing a seed round for a new biotech that aims to use ar­ti­fi­cial in­tel­li­gence to jump in­to the world of organoids.

Vivo­dyne an­nounced the $38 mil­lion seed fi­nanc­ing Wednes­day morn­ing, tout­ing its plat­form’s abil­i­ty to pro­duce hu­man-like tis­sue at every stage of drug de­vel­op­ment. The goal, CEO An­drei Georges­cu told End­points News, is to slash pre­clin­i­cal test­ing times by re­duc­ing the need for an­i­mal test­ing, and use the plat­form to learn how com­pounds will in­ter­act with hu­man cells at scale be­fore ac­tu­al­ly test­ing them in peo­ple.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER